Literature DB >> 22133777

Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation.

Dragana Milojkovic, Amr Ibrahim, Alistair Reid, Letizia Foroni, Jane Apperley, David Marin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22133777      PMCID： PMC3291606          DOI： 10.3324/haematol.2011.057513

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.

Authors:  D Rea; L Legros; E Raffoux; X Thomas; P Turlure; S Maury; B Dupriez; A Pigneux; B Choufi; O Reman; D Stéphane; B Royer; M Vigier; M Ojeda-Uribe; C Recher; H Dombret; F Huguet; P Rousselot
Journal:  Leukemia       Date:  2006-03       Impact factor: 11.528

2.  Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

Authors:  Jorge Cortes; Philippe Rousselot; Dong-Wook Kim; Ellen Ritchie; Nelson Hamerschlak; Steven Coutre; Andreas Hochhaus; Francois Guilhot; Giuseppe Saglio; Jane Apperley; Oliver Ottmann; Neil Shah; Philipp Erben; Susan Branford; Prasheen Agarwal; Ashwin Gollerkeri; Michele Baccarani
Journal:  Blood       Date:  2006-12-21       Impact factor: 22.113

3.  In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.

Authors:  Y Kano; M Akutsu; S Tsunoda; H Mano; Y Sato; Y Honma; Y Furukawa
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

4.  Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.

Authors:  Giuseppe Saglio; Andreas Hochhaus; Yeow Tee Goh; Tamas Masszi; Ricardo Pasquini; Frederic Maloisel; Philipp Erben; Jorge Cortes; Ronald Paquette; M Brigid Bradley-Garelik; Chao Zhu; Herve Dombret
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

5.  Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs.

Authors:  A J Tipping; F X Mahon; G Zafirides; V Lagarde; J M Goldman; J V Melo
Journal:  Leukemia       Date:  2002-12       Impact factor: 11.528

6.  The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).

Authors:  Bénédicte Deau; Franck E Nicolini; Joelle Guilhot; Françoise Huguet; Agnès Guerci; Laurence Legros; Cécile Pautas; Christian Berthou; Denis Guyotat; Pascale Cony-Makhoul; Martine Gardembas; Mauricette Michallet; Sandrine Hayette; Jean Michel Cayuela; Isabelle Radford Weiss; Delphine Réa; Sylvie Castaigne; François-Xavier Mahon; François Guilhot; Philippe Rousselot
Journal:  Leuk Res       Date:  2010-12-10       Impact factor: 3.156

7.  Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia.

Authors:  Jyoti Wadhwa; Richard M Szydlo; Jane F Apperley; Andrew Chase; Marco Bua; David Marin; Eduardo Olavarria; Edward Kanfer; John M Goldman
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

8.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Authors:  B J Druker; C L Sawyers; H Kantarjian; D J Resta; S F Reese; J M Ford; R Capdeville; M Talpaz
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

9.  In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.

Authors:  Barbara Scappini; Francesco Onida; Hagop M Kantarjian; Li Dong; Srdan Verstovsek; Michael J Keating; Miloslav Beran
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860
  9 in total
  8 in total

Review 1.  We do still transplant CML, don't we?

Authors:  Charles F Craddock
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Allogeneic stem cell transplantation for chronic myeloid leukemia.

Authors:  Jiří Pavlů; Jane F Apperley
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

3.  Blast and accelerated phase CML: room for improvement.

Authors:  Joan How; Vinayak Venkataraman; Gabriela Soriano Hobbs
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 4.  Allogeneic transplantation for CML in the TKI era: striking the right balance.

Authors:  Andrew J Innes; Dragana Milojkovic; Jane F Apperley
Journal:  Nat Rev Clin Oncol       Date:  2015-11-17       Impact factor: 66.675

Review 5.  Management of Chronic Myeloid Leukemia in Advanced Phase.

Authors:  Massimiliano Bonifacio; Fabio Stagno; Luigi Scaffidi; Mauro Krampera; Francesco Di Raimondo
Journal:  Front Oncol       Date:  2019-10-25       Impact factor: 6.244

6.  Sequential Use of Second-Generation Tyrosine Kinase Inhibitor Treatment and Intensive Chemotherapy Induced Long-Term Complete Molecular Response in Imatinib-Resistant CML Patient Presenting as a Myeloid Blast Crisis.

Authors:  Masaaki Tsuji; Tatsuki Uchiyama; Chisaki Mizumoto; Tomoharu Takeoka; Kenjiro Tomo; Tatsuharu Ohno
Journal:  Case Rep Hematol       Date:  2017-12-17

Review 7.  European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Authors:  A Hochhaus; M Baccarani; R T Silver; C Schiffer; J F Apperley; F Cervantes; R E Clark; J E Cortes; M W Deininger; F Guilhot; H Hjorth-Hansen; T P Hughes; J J W M Janssen; H M Kantarjian; D W Kim; R A Larson; J H Lipton; F X Mahon; J Mayer; F Nicolini; D Niederwieser; F Pane; J P Radich; D Rea; J Richter; G Rosti; P Rousselot; G Saglio; S Saußele; S Soverini; J L Steegmann; A Turkina; A Zaritskey; R Hehlmann
Journal:  Leukemia       Date:  2020-03-03       Impact factor: 11.528

8.  Impact of frontline treatment approach on outcomes of myeloid blast phase CML.

Authors:  Kapil Saxena; Elias Jabbour; Ghayas Issa; Koji Sasaki; Farhad Ravandi; Abhishek Maiti; Naval Daver; Tapan Kadia; Courtney D DiNardo; Marina Konopleva; Jorge E Cortes; Musa Yilmaz; Kelly Chien; Sherry Pierce; Hagop Kantarjian; Nicholas J Short
Journal:  J Hematol Oncol       Date:  2021-06-15       Impact factor: 17.388
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.